Holiday Sale - 50% OFF Your First 3 Months (applied at checkout)
Sign In Get Started
Toggle Nav
Menu

Important Safety Information

See Important Safety Information, including Boxed Warning, about:

Important Safety Information for Ozempic® (semaglutide)

FDA approved for:

  • Type 2 diabetes (glycemic control)
  • Reducing cardiovascular risk in patients with established CVD

Not approved for:

  • Type 1 diabetes
  • Patients with a history of pancreatitis

Do not use if:

  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
  • Known allergy to semaglutide

Common side effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach pain
  • Low blood sugar

Serious side effects:

  • Thyroid tumors, including MTC
  • Pancreatitis
  • Gallbladder problems (e.g., gallstones)
  • Acute kidney injury, especially with dehydration
  • Diabetic retinopathy complications
  • Severe allergic reactions (anaphylaxis, angioedema)
  • Hypoglycemia (with insulin or sulfonylureas)

This information is not comprehensive. Please see the full Prescribing Information for complete safety information.

Important Safety Information for Zepbound® (tirzepatide)

FDA approved for:

  • Chronic weight management in adults with obesity or overweight and at least one weight-related condition

Do not use if:

  • Personal or family history of MTC or MEN 2
  • Known allergy to tirzepatide

Common side effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Indigestion
  • Injection site reactions
  • Abdominal pain
  • Fatigue
  • Belching
  • Hair loss
  • Acid reflux (GERD)

Serious side effects:

  • Thyroid tumors, including MTC
  • Pancreatitis
  • Gallbladder problems
  • Acute kidney injury
  • Severe dehydration from GI issues
  • Hypoglycemia (with insulin or sulfonylureas)
  • Suicidal thoughts or behaviors
  • Severe allergic reactions

This information is not comprehensive. Please see the full Prescribing Information for complete safety information.

Important Safety Information for Mounjaro® (tirzepatide)

FDA approved for:

  • Type 2 diabetes (glycemic control)

Not approved for:

  • Type 1 diabetes
  • Patients with a history of pancreatitis

Do not use if:

  • Personal or family history of MTC or MEN 2
  • Known allergy to tirzepatide

Common side effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach pain

Serious side effects:

  • Thyroid tumors, including MTC
  • Pancreatitis
  • Gallbladder problems
  • Acute kidney injury
  • Severe allergic reactions
  • Hypoglycemia (with certain medications)
  • Suicidal ideation or mood changes

Important Safety Information for Wegovy® (semaglutide)

FDA approved for:

  • Chronic weight management
  • Cardiovascular risk reduction in overweight/obese patients with known CVD

Do not use if:

  • Personal or family history of MTC or MEN 2
  • Known allergy to semaglutide

Common side effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach pain
  • Dyspepsia
  • Belching
  • Flatulence
  • Gastroenteritis
  • GERD
  • Abdominal distension
  • Dizziness

Serious side effects:

  • Thyroid tumors, including MTC
  • Pancreatitis
  • Gallbladder problems
  • Acute kidney injury
  • Diabetic retinopathy complications
  • Hypoglycemia
  • Suicidal thoughts or behaviors
  • Severe allergic reactions
  • Severe gastrointestinal reactions
  • Increased heart rate
  • Pulmonary aspiration during sedation or anesthesia

This information is not comprehensive. Please see the full Prescribing Information for complete safety information.

Shared Black Box Warning (All Medications Above):

Animal studies identified an increased risk of Thyroid C-cell Tumors. Whether this risk exists in humans is unknown. Do not use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

Do not combine GLP-1 receptor agonists (e.g., Ozempic®, Saxenda®, Victoza®, Byetta®, or Bydureon®).

How should my medication be administered?

These medications are self-administered subcutaneous injections once weekly (thigh, stomach, or upper arm). Rotate the injection site each week. They may be taken with or without food. If you miss a dose and it’s been less than 5 days, take it as soon as possible. If more than 5 days have passed, skip the missed dose and resume your regular schedule.

What should I tell my provider before using my medication?

Share your full medical history, especially if you have or have had: type 1 or 2 diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, gallbladder problems, depression, or suicidal thoughts.

Also, tell your provider about all medications, vitamins, and supplements you take. Some medications to watch for include insulin, sulfonylureas (glipizide, glyburide), and oral agents that lower blood sugar.

GLP-1 receptor agonists should not be used during pregnancy or breastfeeding.

Remember: Never share your injector pen.

This summary is for educational purposes only and does not replace medical advice. Always consult your physician before making any changes to your treatment plan.

Important Safety Information for Victoza® (liraglutide)

FDA approved for:

  • Type 2 diabetes (glycemic control)
  • Reducing cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease

Not approved for:

  • Type 1 diabetes
  • Patients with a history of pancreatitis
  • Weight loss as a standalone indication (that is Saxenda®)

Do not use if:

  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
  • Known allergy to liraglutide

Common Side Effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach pain
  • Headache
  • Indigestion
  • Fatigue
  • Injection-site reactions

Serious Side Effects:

  • Thyroid tumors, including MTC
  • Pancreatitis
  • Gallbladder problems (e.g., gallstones)
  • Acute kidney injury (especially when dehydrated)
  • Severe allergic reactions (anaphylaxis, angioedema)
  • Hypoglycemia, especially when used with insulin or sulfonylureas
  • Suicidal thoughts or behaviors (rare)

Shared Black Box Warning (GLP-1 Medications):

Animal studies identified an increased risk of thyroid C-cell tumors. It is not known whether this risk exists in humans. Do not use if you or a family member has MTC or MEN 2.

Do not use Victoza with any other GLP-1 receptor agonist:

Includes: Ozempic®, Wegovy®, Saxenda®, Mounjaro®, Zepbound™, Byetta®, Bydureon®

How should Victoza be administered?

  • Inject once daily in the thigh, stomach, or upper arm.
  • Can be taken with or without food.
  • Rotate injection sites daily.
  • Follow your provider’s prescribed dosing schedule.
  • Do not change your dose or stop your medication without speaking to your provider.

What should I tell my provider before using Victoza?

Share your full medical history, especially if you have:

  • Type 1 or type 2 diabetes
  • Thyroid cancer or nodules
  • Pancreatitis or gallbladder disease
  • Kidney disease
  • GI conditions like gastroparesis
  • Depression or history of suicidal thoughts

Medications to discuss with your provider:

  • Diabetes medications (risk of low blood sugar when combined)
  • All prescription meds, OTC meds, vitamins, and supplements
  • Victoza should not be used during pregnancy or breastfeeding.

Emergency Symptoms — Seek Immediate Care If You Experience:

  • Difficulty breathing or swelling of the face/throat
  • Severe abdominal pain, nausea, or vomiting (possible pancreatitis)
  • Persistent vomiting or inability to stay hydrated
  • Fainting, dizziness, or symptoms of dehydration

Important Reminders:

  • Never share your pen.
  • Rotate injection sites to reduce irritation.
  • Store medication as instructed.
  • Contact your provider if side effects worsen or do not improve.

Important Safety Information for Saxenda® (liraglutide)

FDA approved for:

  • Chronic weight management in adults with obesity or overweight plus at least one weight-related condition

Not approved for:

  • Type 1 diabetes
  • Patients with a history of pancreatitis

Do not use if:

  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
  • Known allergy to liraglutide

Common Side Effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach pain
  • Headache
  • Fatigue
  • Injection-site reactions
  • Indigestion
  • Belching

Serious Side Effects:

  • Thyroid tumors, including MTC
  • Pancreatitis
  • Gallbladder problems (e.g., gallstones)
  • Acute kidney injury, especially with dehydration
  • Severe gastrointestinal issues
  • Severe allergic reactions (anaphylaxis, angioedema)
  • Suicidal thoughts or behaviors (rare)

Shared Black Box Warning (GLP-1 Medications):

Animal studies identified an increased risk of thyroid C-cell tumors. It is not known whether this risk exists in humans. Do not use if you or a family member has MTC or MEN 2.

Do not use Saxenda with any other GLP-1 receptor agonist:

Includes: Ozempic®, Wegovy®, Victoza®, Mounjaro®, Zepbound®, Byetta®, Bydureon®

How should Saxenda be administered?

  • Inject once daily in the thigh, stomach, or upper arm.
  • Rotate injection sites daily.
  • Can be taken with or without food.
  • Follow the dosage schedule provided by your provider.
  • Do not change your dose or stop your medication without speaking to your provider.

What should I tell my provider before using Saxenda?

Share your full medical history, especially if you have:

  • Type 1 or type 2 diabetes
  • Thyroid cancer or nodules
  • Pancreatitis
  • Gallbladder disease
  • Kidney disease
  • Gastroparesis or significant GI conditions
  • Depression or history of suicidal thoughts

Medications to discuss with your provider:

  • Diabetes medications (risk of low blood sugar when combined)
  • Any medications requiring precise absorption due to delayed gastric emptying
  • All prescription meds, OTC meds, vitamins, and supplements

Saxenda should not be used during pregnancy or breastfeeding.

Emergency Symptoms — Seek Immediate Care If You Experience:

  • Difficulty breathing or swelling of the face/throat
  • Severe abdominal pain (possible pancreatitis or gallbladder issue)
  • Persistent vomiting or inability to stay hydrated
  • Fainting, dizziness, or signs of dehydration

Important Reminders:

  • Never share your pen.
  • Rotate injection sites to reduce skin irritation.
  • Store medication as directed.
  • Contact your provider if side effects become severe or do not improve.

Important Safety Information for Rybelsus® (semaglutide)

FDA approved for:

  • Type 2 diabetes (glycemic control) in adults
  • Reducing cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease

Not approved for:

  • Type 1 diabetes
  • Patients with a history of pancreatitis
  • Weight loss (Wegovy® is the weight-management formulation)

Do not use if:

  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
  • Known allergy to semaglutide

Common Side Effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach pain
  • Indigestion
  • Belching
  • Fatigue
  • Decreased appetite

Serious Side Effects:

  • Thyroid tumors, including MTC
  • Pancreatitis
  • Gallbladder problems (e.g., gallstones)
  • Acute kidney injury (especially when dehydrated)
  • Severe allergic reactions (anaphylaxis, angioedema)
  • Diabetic retinopathy complications
  • Hypoglycemia (especially when taken with insulin or sulfonylureas)
  • Suicidal thoughts or behaviors (rare)

Shared Black Box Warning (GLP-1 medications):

Animal studies identified an increased risk of thyroid C-cell tumors. It is unknown whether this risk applies to humans. Do not use if you or a family member has MTC or MEN 2.

Do not use Rybelsus with any other GLP-1 receptor agonist:

Includes: Ozempic®, Wegovy®, Saxenda®, Victoza®, Mounjaro®, Zepbound™, Byetta®, Bydureon®

How should Rybelsus be taken?

  • Take once daily, by mouth.
  • Take on an empty stomach with no more than 4 oz (½ cup) of water.
  • Wait at least 30 minutes before eating, drinking, or taking other medications.
  • Follow your provider’s titration schedule.
  • Do not change your dose or stop your medication without talking to your provider.

What should I tell my provider before using Rybelsus?

Share your full medical history, especially if you have:

  • Type 1 or type 2 diabetes
  • Thyroid cancer or nodules
  • Pancreatitis
  • Gallbladder disease
  • Kidney disease
  • GI disorders like gastroparesis
  • Depression or history of suicidal thoughts

Medications to discuss with your provider:

  • Diabetes medications (risk of hypoglycemia when combined)
  • Any medications that require consistent absorption, since Rybelsus affects gastric emptying
  • All prescription meds, OTC meds, vitamins, and supplements

Rybelsus should not be used during pregnancy or breastfeeding.

Emergency Symptoms — Seek Immediate Care If You Experience:

  • Difficulty breathing or swelling of the face/throat
  • Severe, persistent abdominal pain (possible pancreatitis or gallbladder issue)
  • Ongoing vomiting or inability to stay hydrated
  • Severe dizziness, fainting, or signs of dehydration

Important Reminders:

  • Never share your medication.
  • Take exactly as directed for best absorption.
  • Notify your provider if side effects become severe or do not improve.
  • Store medication properly and keep tablets in their original packaging.
© 2025 Balto Health Inc. All Rights reserved.